Kết quả tìm kiếm - Flavia Ejzykowicz
- Đang hiển thị 1 - 6 kết quả của 6
-
1
Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA Bằng Min Huang, Gilberto Lopes, Ralph P. Insinga, Thomas Burke, Flavia Ejzykowicz, Ying Zhang, Josephine Feliciano
Được phát hành 2019Artigo -
2
Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated... Bằng Kevin M. Pantalone, Brian J. Wells, Kevin Chagin, Flavia Ejzykowicz, Changhong Yu, Alex Milinovich, Janine Bauman, Michael W. Kattan, Swapnil Rajpathak, Robert S. Zimmerman
Được phát hành 2016Artigo -
3
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, rando... Bằng David Cella, Robert J. Motzer, Cristina Suárez, Steven I. Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel Wallace, Burçin Şimşek, Joshua Zhang, Cristina Ivanescu, Andrea B. Apolo, Toni K. Choueiri
Được phát hành 2022Artigo -
4
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data Bằng Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher D. Lao, Jean‐Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana García-Horton, Zheng‐Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein A. Tawbi, Dirk Schadendorf
Được phát hành 2024Artigo -
5
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma Bằng Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir
Được phát hành 2022Artigo -
6
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Bằng Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer
Được phát hành 2021Artigo
Công cụ tìm kiếm:
Các môn học liên quan
Internal medicine
Medicine
Cancer
Immunotherapy
Oncology
Nivolumab
Renal cell carcinoma
Sunitinib
Cabozantinib
Confidence interval
Hazard ratio
Ipilimumab
Randomized controlled trial
Urology
Cancer research
Chemotherapy
Clinical endpoint
Combination therapy
Cost effectiveness
Diabetes mellitus
Endocrinology
Glycemic
Kidney cancer
Lung cancer
Metformin
Open label
Overall survival
PD-L1
Pediatrics
Pembrolizumab